Late toxicity after radical treatment for locally advanced head and neck cancer

Oral Oncology

Volumn 51, Issue 8, 2015, Pages 795-799

  Taberna, Miren ^a,b   Rullan, Antonio José ^a,b   Hierro, Cinta ^c   Navarro, Valentín ^a   Vázquez, Silvia ^a   Lozano, Alicia ^a   Vilajosana, Esther ^a   Maños, Manel ^a,b,d   Marí, Antonio ^a,b,e   Viñals, Joan ^a,b,f   Mesía, Ricard ^a,b  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e Hospital Universitari de Bellvitg Feixa Llarga   (Spain)

^f Plastic and Reconstructive Surgery Department   (Spain)

Author keywords

Cetuximab; Cisplatin; Head and neck cancer; Late toxicity; Locally advanced head and neck carcinomas; Long survivors; Quality of life; Quality of life (QoL); Radiotherapy

Indexed keywords

CETUXIMAB; CISPLATIN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALCOHOL CONSUMPTION; ANOREXIA; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVOR; CHEMORADIOTHERAPY; CLINICAL PRACTICE; DAILY LIFE ACTIVITY; DISEASE ASSESSMENT; DISEASE SEVERITY; DYSPHAGIA; FATIGUE; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; INDUCTION CHEMOTHERAPY; JAW OSTEONECROSIS; LARYNX DISORDER; LOCALLY ADVANCED HEAD AND NECK CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RISK FACTOR; SALIVA; SCORING SYSTEM; SIDE EFFECT; SKIN MANIFESTATION; SMOKING; SPEECH DISORDER; TONGUE DISEASE; TRISMUS; XEROSTOMIA; ADVERSE EFFECTS; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; MIDDLE AGED; PROCEDURES; QUESTIONNAIRE; STATISTICAL MODEL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CETUXIMAB; CHEMORADIOTHERAPY; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; RISK FACTORS; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84942818532     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2015.05.002     Document Type: Article

References (14)

1. Rodriguez CP, Adelstein DJ. Survival trends in head and neck cancer: opportunities for improving outcomes. The Oncologist 2010;15(9):921-3. http://dx.doi.org/10.1634/theoncologist.2010-0237.
2. O'Rorke MA, Ellison MV, Murray LJ, Moran M, James J, Anderson LA. Human papillomavirus related head and neck cancer survival: a systematic review and meta-analysis. Oral Oncol 2015;48(12):1191-201. http://dx.doi.org/10.1016/j.oraloncology.2012.06.019.
3. Studer G, Huguenin PU, Davis JB, Kunz G, Lutolf UM, Glanzmann C. IMRT using simultaneously integrated boost (SIB) in head and neck cancer patients. Radiat Oncol 2006;2006 1(1):7. http://dx.doi.org/10.1186/1748-717X-1-7.
4. Pignon JP, Maître A Le, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009;92(1):4-14. http://dx.doi.org/10.1016/j.radonc.2009.04.014.
5. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Eng J Med 2006;354(6):567-78. http://dx.doi.org/10.1056/NEJMoa053422.
6. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unrespectable head and neck cancer. N Eng J Med 2007;357(17):1695-704. http://dx.doi.org/10.1056/NEJMoa071028.
7. Bentzen SM, Trotti A. Evaluation of early and late toxicities in chemoradiation trials. J Clin Oncol 2007;25(26):4096-103. http://dx.doi.org/10.1200/JCO.2007. 13.3983.
8. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol 2015;31(5):1341-6. http://dx.doi.org/10.1016/0360-3016(95)00060-C.
9. TrottiA. Toxicity inheadand neck cancer: a reviewof trends andissues. Int J Radiat Oncol 2015;47(1):1-12. http://dx.doi.org/10.1016/S0360-3016(99)00558-1.
10. Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 2008;26(21):3582-9. http://dx.doi.org/10.1200/JCO.2007.14.8841.
11. Caudell JJ, Schaner PE, Meredith RF, Locher JL, Nabell LM, Carroll WR, et al. Factors associated with long-term dysphagia after definitive radiotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol 2009;73(2):410-5. http://dx.doi.org/10.1016/j.ijrobp.2008.04.048.
12. Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 1997;3(12):2703-7.
13. Bonner Ja, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. The Lancet Oncol 2010;11:21-8. doi:10.1016/S1470-2045(09)70311-0.
14. Lefebvre JL, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C, et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J Clin Oncol 2013;31(7):853-9. http://dx.doi.org/10.1200/JCO.2012.42.3988.